natgillin/translations-raw huggingface dataset:
The compounds for use according to any of claims 16 to 19, wherein the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, parkinsonism (linked to chromosome 17, FTDP-17), Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, and multiple system atrophy. 
Spojevi za uporabu prema bilo kojem od zahtjeva 16 do 19, naznačeni time da je neurodegenerativni poremećaj odabran od Alzheimerove bolesti, Pickove bolesti, kortikobazalne degeneracije, progresivne supranuklearne paralize, frontotemporalne demencije, Parkinsonizma (vezanog na kromosom 17, FTDP-17), Parkinsonove bolesti, difuzne bolesti Lewyevih tjelešaca, traumatske ozljede mozga, amiotrofne lateralne skleroze, Niemann-Pickove bolesti, sindroma Hallervorden-Spatz, Downovog sindroma, neuroaksonske distrofije, te multiple sistemske atrofije.
is a single bond or carbonyl, 
je jednostavna veza ili karbonil;
with the following provisos: 
uz slijedeće uvjete:
The compound of claim 2 having formula Ic and pharmaceutically acceptable salts and solvates thereof, wherein a depicts the bond linking R1 to the piperazine moiety, and Ar1, Ar2, R1, R1', X1, and X2 are as defined in claim 2. 
Spoj u skladu s patentim zahtjevom 2 koji sadrži formulu Ic [image] i njegove farmaceutski prihvatljive soli i solvati, pri čemu a prikazuje poveznicu koja povezuje R1za piperazin dio, i Ar1, Ar2, R1, R1’, X1i X2su kao što su definirani u patentnom zahtjevu 2.
and R6 are independently selected from H, halo, cyano, alkyl, cyclopropyl, aryl, heteroaryl, each of said aryl and heteroaryl groups being optionally substituted by one or more group(s) selected from halo, alkyl, cyclopropyl, or R5 and R6 together form a phenyl moiety fused to the phenyl ring they are attached to; and 
i R6 su neovisno odabrani od H, halo, cijano, alkil, ciklopropil, aril, heteroaril, svaka od spomenutih aril i heteroaril skupina je izborno supstituirana s jednom ili više skupina odabranih od halo, alkil, ciklopropil, ili R5 i R6 zajedno tvore fenil dio fuzioniran s fenil prstenom za koji su povezani, i
is a heterocyclyl, aryl or heteroaryl group, each of said groups being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy or hydroxyl; 
je heterociklil, aril ili heteroaril skupina, svaka od spomenutih skupina je izborno supstituirana s jednom ili više skupina odabranih od halo, cijano, alkil, haloalkil, ciklopropil, alkoksi, haloalkoksi ili hidroksil;
is H, methyl or R17 together with R16 forms a cycloalkyl or aryl moiety fused to the thiazolyl group to which they are attached, thus forming a fused ring system, said fused ring system being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy or hydroxyl; and 
je H, metil ili R17 zajedno s R16 tvori cikloalkil ili aril dio fuzioniran s tiazolil skupinom za koju su vezani, tako tvoreći fuzionirani sustav prstena, spomenuti fuzionirani sustav prstena je izborno supstituiran s jednom ili više skupina odabranih od halo, cijano, alkil, haloalkil, ciklopropil, alkoksi, haloalkoksi ili hidroksil; i
R11, R12, R12' and R13 are independently selected from H, halo, C1-C3 alkyl, hydroxyl, methoxy, or R12 together with R11 or R13 forms an aryl or heterocyclyl or heteroaryl moiety fused to the pyridyl group to which they are attached and being optionally substituted by one or more group(s) selected from halo, C1-C3 alkyl, methoxy or hydroxyl, then, 
, R12, R12’ i R13 su neovisno odabrani od H, halo, C1-C3alkil, hidroksil, metoksi, ili zajedno s R11 ili R13 tvori aril ili heterociklil ili heteroaril dio fuzioniran s piridil skupinom za koju su vezani i izborno je supstituirana s jednom ili više skupina odabranih od halo, C1-C3 alkil, metoksi ili hidroksil, tada, Ar1 je fenil, 3-halofenil, 4-halofenil, 2,3-dihlorofenil, 3,4-dihalofenil, 3,4,5-trihalofenil, 4-cijanofenil, 4-(C1-C3alkil)fenil, 4-(C1 haloalkil)fenil, i
together with R16 forms a cycloalkyl or aryl moiety fused to the thiazolyl group to which they are attached, thus forming a fused ring system, said fused ring system being optionally substituted by one or more group(s) selected from halo, C1-3 alkyl, methoxy or hydroxyl, then Ar1 is phenyl, 3-halophenyl, 4-halophenyl, 2,3-dichlorophenyl, 3,4-dihalophenyl, 3,4,5-trihalophenyl, 4-cyanophenyl, 4-(C1-C3 alkyl)phenyl, 4-(C1 haloalkyl)phenyl, and 
zajedno s R16 formira cikloalkil ili aril dio fuzionirani s tiazolil skupinom za koju su povezani, tako tvoreći fuzionirani sustav prstena, spomenuti fuzionirani sustav prstena je izborno supstituiran s jednom ili više skupina odabranih od halo, C1-3 alkil, metoksi ili hidroksil, tada Ar1 je fenil, 3-halofenil, 4-halofenil, 2,3-dihlorofenil, 3,4-dihalofenil, 3,4,5-trihalofenil, 4-cijanofenil, 4-(C1-C3alkil)fenil, 4-(C1 haloalkil)fenil, i
and R16 form together with the thiazolyl group to which they are attached a benzothiazol-2-yl or 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl moiety. 
i R16 tvore zajedno s tiazolil skupinom za koju su vezani benzotiazol-2-il ili 4,5,6,7-tetrahidro-1,3-benzotiazol-2-il dio.
The compound of claim 6 selected from formulae Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 and pharmaceutically acceptable salts, and solvates thereof, wherein a depicts the bond linking R1 to the piperazine moiety; and Ar1, R1, X1 and X2 are as defined in claim 2; and 
Spoj u skladu s patentnim zahtjevom 6 odabrano iz formula Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 i Ig-8 [image] i njegove farmaceutski prihvatljive soli i solvati,pri tome a prikazuje poveznicu koja povezuje R1 s piperazin dijelom; i Ar1, R1, X1i X2su kao što su definirani u patentnom zahtjevu 2; i
a depicts the bond linking R1 to the piperazine moiety; and 
a prikazuje poveznicu koja povezuje R1 za piperazin dio; i
The compound of claim 1 selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1 odabrano iz skupine koja se sastoji od:
follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility), gynecological disorders, infertility and androgen-producing tumor (virilizing ovarian or adrenal tumor). 
zaustavljanje sazrijvanja folikula, atrezija, anovulacija, dismenoreja, disfuncionalno krvarenje maternice, neplodnost), ginekološki poremećaji, neplodnost i tumor koji proizvodi androgen (virilizujući ovarijalni ili adrenalni tumor).
A cell according to claim 5 or claim 6, wherein the polynucleotide sequence encoding Ero1 encodes the polypeptide sequence given in SEQ ID NO: 3. 
Stanica prema zahtjevu 5 ili zahtjevu 6, naznačena time da polinukleotidna sekvenca koja kodira Ero1, kodira polipeptidnu sekvencu navedenu u SEQ ID NO: 3.
A cell according to claim 8 or claim 9, wherein the polynucleotide sequence encoding XBP1 encodes human XBP1 and encodes the polypeptide sequence given in SEQ ID NO:1. 
Stanica prema zahtjevu 8 ili zahtjevu 9, naznačena time da polinukleotidna sekvenca koja kodira XBP1, kodira ljudski XBP1 i kodira polipeptidnu sekvencu navedenu u SEQ ID NO:1.
A CHOSXE cell line as deposited on 10th February 2010 (Depositor Identification in Full: CHOS. 
CHOSXE stanična linija kako je deponirana dana 10 veljače 2010 (cjelokupna depozitna identifikacija: CHOS.
Ero1a), at the European Collection of Cell Cultures (ECACC), HPA, United Kingdom, under HPA Culture Collections Reference Number: Q8515 and Accession number: 10021001 in accordance with The Budapest Treaty. 
Ero1a), kod European Collection of Cell Cultures (ECACC), HPA, Ujedinjeno Kraljevstvo, pod HPA kolekcijom kultivata Referentni broj: i pristupni broj: 10021001 u skladu s Budimpeštanskim Ugovorom.
measuring the quantity of Ero1 mRNA and/or protein in the selected one or more cell clones; 
mjerenje količine Ero1 mRNA i/ili proteina u odabranom jednom ili više staničnih klonova;
measuring the quantity of XBP1 mRNA and/or protein in the selected one or more clones: 
mjerenje količine XBP1 mRNA i/ili proteina u odabranom jednom ili više klonova:
selecting one or more modified cell clones having a higher quantity of Ero1 mRNA and/or protein and XBP1 mRNA and/or protein compared to the unmodified cell clone. 
odabir jednog ili više modificiranih staničnih klonova koji imaju veću količinu Ero1 mRNA i/ili proteina i XBP1 mRNA i/ili proteina u usporedbi s nemodificiranim staničnim klonom.
An expression system according to claim 25, wherein the expression system comprises the Ero1 and XBP1 polynucleotides as defined in claim 3 
Ekspresijski sustav prema zahtjevu 25, naznačen time da ekspresijski sustav sadrži Ero1 i XBP1 polinukleotide kako je definirano u zahtjevu 3
represents a group selected from: wherein "*" indicates the point of attachment to the phenyl ring R2 is attached to; 
predstavlja skupinu odabranu od: [image] pri čemu "*" označava točku spajanja na fenilni prsten na koju je spojen R2;
and R5, independently from each other, represent a group selected from a hydrogen atom and a C1-C3-alkyl- group, 
i R5, međusobno neovisno, predstavljaju skupinu odabranu od vodikovog atoma i skupine C1-C3-alkil-, ili
and R5, together with the carbon atom to which they are attached, form a C3-C6-cycloalkyl ring; 
i R5, zajedno s ugljikovim atomom na koju su oni vezani, tvore C3-C6-cikloalkilni prsten;
represents a group or R9 represents a group selected from: wherein "**" indicates the point of attachment to the carbonyl group R9 is attached to; 
predstavlja skupinu [image] ili R9 predstavlja skupinu odabranu od: [image] pri čemu "**" označava točku spajanja na karbonilnu skupinu na koju je spojen R9;
and R11, independently from each other, represent a group selected from a hydrogen atom and a C1-C3-alkyl- group, or 
i R11, međusobno neovisno, predstavljaju skupinu odabranu od vodikovog atoma i skupine C1-C3-alkil-, ili
and R11, together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl ring; 
i R11, zajedno s dušikovim atomom na koju su oni vezani tvore 4- do 7-člani heterocikloalkilni prsten;
RA represents a group: 
RA predstavlja skupinu:
C1-C6-alkyl, substituted one or more times, identically or differently, with a group selected from: -NH2, -N(H)R10, -N(R10)R11, 
-C6-alkila, supstituiranog jednom ili više puta, istovjetno ili različito, sa skupinom odabranom od: NH2, -N(H)R10, -N(R10)R11,
represents a group selected from: wherein "**" indicates the point of attachment to the carbonyl group R9 is attached to, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same. 
predstavlja skupinu odabranu od: [image] [image] [image] pri čemu "**" označava točku spajanja na karbonilnu skupinu na koju je spojen R9, ili tautomer, N-oksid, hidrat, solvat, ili njihova sol ili smjesa istih.
and R11, independently from each other, represent a group selected from a hydrogen atom and a C1-C3-alkyl- group, 
i R11, međusobno neovisno, predstavljaju skupinu odabranu od vodikovog atoma i skupine C1-C3-alkil-, ili tautomer, N-oksid, hidrat, solvat, ili njihova sol ili smjesa istih.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, and a pharmaceutically acceptable diluent or carrier. 
Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 13, ili tautomer, N-oksid, hidrat, solvat, ili njihovu sol, naročito farmaceutski prihvatljivu sol, ili smjesu od istih, te farmaceutski prihvatljiv razrjeđivač ili nosač.
wherein, a maximum of two dotted lines selected from the five dotted lines are a double bond; 
svaka isprekidana crta pojedinačno predstavlja proizvoljnu dvostruku vezu, pri čemu najviše dvije isprekidane crte odabrane od pet isprekidanih crta su dvostruka veza;
B is cyclic structure selected from the group consisting of cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; 
B predstavlja cikličku strukturu odabranu od cikloalkila; cikloalkenila; cikloalkinila; arila; i heterocikla;
wherein the alkyl, alkenyl and alkynyl can be unsubstituted or substituted with Z; and 
* i pri čemu navedeni alkil, alkenil i alkinil može biti nesupstituiran ili supstituiran sa Z;
wherein the alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, the heteroatom selected from the group consisting of O, S and N; and 
* i pri čemu navedeni alkil, alkenil, alkinil, aril, heterocikl, arilalkilen, arilalkenilen, arilalkinilen, heterociklički-alkilen, heterociklički-alkenilen ili heterociklički-alkinilen proizvoljno sadrži jedan ili više heteroatoma u skupini alkil(en), alkenil(en) ili alkinil(en), navedeni heteroatom je odabran od O, S i N;
is selected from the group consisting of hydrogen; alkyl; alkenyl; and alkynyl; 
R" je odabran od vodika; alkila; alkenila; i alkinila;
wherein said alkyl, alkenyl, or alkynyl can be unsubstituted or substituted with Z; and 
* i pri čemu navedeni alkil, alkenil i alkinil može biti nesupstituiran ili supstituiran sa Z;
wherein, a maximum of two dotted lines selected from the five dotted lines of formula (A1) are a double bond; 
svaka isprekidana crta pojedinačno predstavlja proizvoljnu dvostruku vezu, pri čemu najviše dvije isprekidane crte koje su odabrane od pet isprekidanih crta su dvostruka veza;
B represents a cyclic structure selected from the group consisting of cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; 
B predstavlja cikličku strukturu odabranu od cikloalkila; cikloalkenila; cikloalkinila; arila; i heterocikla;
wherein said alkyl, alkenyl and alkynyl can be unsubstituted or substituted with Z; and 
* i pri čemu navedeni alkil, alkenil i alkinil može biti nesupstituiran ili supstituiran sa Z;
each R10 is independently selected from the group consisting of alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; C5-14arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene; and heterocycle-alkynylene; wherein said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N; and 
svaki R10 je neovisno odabran od alkila; alkenila; alkinila; arila; heterocikla; arilalkilena; arilalkenilena; arilalkinilena; heterocikličkog-alkilena; heterocikličkog-alkenilena ili heterocikličkog-alkinilena; * i pri čemu navedeni alkil, alkenil, alkinil, aril, heterocikl, arilalkilen, arilalkenilen, arilalkinilen, heterociklički-alkilen, heterociklički-alkenilen ili heterociklički-alkinilen proizvoljno sadrži jedan ili više heteroatoma u skupini alkil(en), alkenil(en) ili alkinil(en), navedeni heteroatom je odabran od O, S i N;
wherein R12 and R13 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted; 
* i pri čemu R12 i R13 mogu se uzeti zajedno tako da tvore (5-, 6-, ili 7-člani) heterocikal koji može biti nesupstituiran ili supstituiran;
The system (10) according to claims 2, wherein said conveyer assembly has a variable conveying velocity. 
Sustav (10) prema zahtjevu 2, naznačen time, da navedeni transportni sklop ima promjenjivu transportnu brzinu.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 1, wherein the anti-CTLA-4 antibody is selected from the group consisting of ipilimumab and tremelimumab. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 1, gdje je anti-CTLA-4 antitijelo odabrano iz grupe koja se sastoji od ipilimumaba i tremelimumaba.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 1, wherein the anti-CTLA-4 antibody is ipilimumab. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 1, gdje anti-CTLA-4 antitijelo je ipilimumab.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 3, wherein said cancer is a solid tumor. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, gdje je navedeni rak solidni tumor.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 9, wherein said anti-proliferative cytotoxic agent is cisplatin. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 9, gdje navedeni anti-proliferativni citotoksični agens je cisplatin.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 9, wherein said anti-proliferative agent is carboplatin. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 9, gdje navedeni anti-proliferativni agens je karboplatin.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 13, wherein 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof is administered daily. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 13, gdje navedeni anti-CTLA4 je administriran otprilike svaka tri tjedna.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 14, wherein said anti-CTLA4 is administered about every three weeks. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 14, gdje je rak sitnostanični rak pluća.
The pharmaceutical composition for use according to any one of claims 1 to 7, wherein said food comprises a meal selected from the group consisting of a moderate-calorie, moderate-fat meal of about 575 calories and fat accounting for about 23% of the total calorie content; a high-calorie, high-fat meal of about 1000 calories and fat accounting for about 50% of the total calorie content; and a meal that falls within a range defined by said moderate-calorie, moderate-fat meal and said high-calorie, high-fat meal. 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1 do 7, naznačen time da navedena hrana sadrži obrok izabran iz skupine koju čine umjereno kaloričan obrok s umjerenim sadržajem masti od oko 575 kalorija, a mast iznosi oko 23% ukupnog kalorijskog sadržaja; visoko kalorijski obrok sa visokim sadržajem masti od oko 1000 kalorija, a mast čini oko 50% ukupnog kalorijskog sadržaja; i obrok koji pripada u okvir opsega definiranog navedenim umjereno kaloričnim obrokom s umjerenim sadržajem masti i navedenim visoko kaloričnim obrokom sa visokim sadržajem masti.
The pharmaceutical composition for use according to any one of the preceding claims, wherein the treatment schedule for said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or pharmaceutically acceptable salt thereof is: 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da raspored davanja navedenog naltreksona ili njegove farmaceutski prihvatljive soli i navedenog bupropiona ili njegove farmaceutski prihvatljive soli je:
about 8 mg of said naltrexone or a pharmaceutically acceptable salt thereof and about 90 mg of said bupropion or a pharmaceutically acceptable salt thereof for the first week of treatment; 
oko 8 mg navedenog naltreksona ili njegove farmaceutski prihvatljive soli i oko 90 mg navedenog bupropiona ili njegove farmaceutski prihvatljive soli u toku prvog tjedna tretmana;
The pharmaceutical composition for use according to any one of the preceding claims, wherein said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or pharmaceutically acceptable salt thereof are administered as two 8 mg tablets of sustained-release naltrexone twice daily and two 90 mg tablets of sustained-release bupropion twice daily. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i navedeni bupropion ili njegova farmaceutski prihvatljiva sol daju kao dvije tablete od 8 mg naltreksona s usporenim oslobađanjem dva puta dnevno i dvije tablete od 90 mg bupropiona s usporenim oslobađanjem dva puta dnevno.
The pharmaceutical composition for use according to any one of the preceding claims, wherein said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or pharmaceutically acceptable salt thereof are administered for at least 56 weeks. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i navedeni bupropion ili njegova farmaceutski prihvatljiva sol daju tijekom najmanje 56 tjedana.
(R)-3-amino-4-(4-fluorophenyl)-N-(4-(4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-yl)butanamide; as well as any pharmaceutically acceptable salt, hydrate, solvate, polymorph, tautomers, geometrical isomers, or optically active forms thereof. 
-3-amino-4-(4-fluorofenil)-N-(4-(4-fluorofenil)-1,3-dimetil-1H-pirazol-5-il)butanamid; kao i bilo koja farmaceutski prihvatljiva sol, hidrat, solvat, polimorf, tautomeri, geometrijski izomeri ili njihovi optički aktivni oblici.
A pyrazole derivative for use according to claim 10 wherein the pyrazole derivative is to be administered in combination with a co-agent useful in the treatment of malaria. 
Derivat pirazola za upotrebu prema zahtjevu 10 pri čemu derivat pirazola treba da bude administriran u kombinaciji sa ko-agensom korisnim u liječenju malarije.
A peptide or composition for use according to claim 7, wherein the subject has haemophilia A, and is undergoing, or is about to undergo, factor VIII replacement therapy and/or FVIII by-passing therapy. 
Peptid ili pripravak za uporabu prema zahtjevu 7, naznačen time da subjekt ima hemofiliju A, i podvrgava se, ili uskoro će se podvrgnuti, zamjenskoj terapiji faktorom VIII i/ili prolaznoj terapiji sa FVIII.